Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy

HIV Medicine

Volumn 7, Issue 7, 2006, Pages 451-456

  Buchacz, Kate ^a   Brooks, John T ^a   Tong, Tony ^a   Moorman, Anne C ^a   Baker, Rose K ^b   Holmberg, S D ^c   Greenberg, A ^a   Wood, Kathleen C ^b   Armon, Carl ^b   Richardson, James T ^b   Palella, Frank J ^d   Chmiel, Joan S ^d   Kirby, Katharine A ^d   Cheley, Janet ^d   Murphy, Tiffany ^d   Lichtenstein, Kenneth A ^e   Greenberg, Kenneth S ^f   Young, Benjamin ^f   Widick, Barbara ^f   Stewart, Cheryl ^f   Zellner, Peggy ^f   Yangco, Bienvenido G ^g   Halkias, Kalliope ^g   Lay, Arletis ^g   Ward, Douglas J ^h   Owen, Charles A ^h   Fuhrer, Jack ⁱ   Ording Bauer, Linda ⁱ   Kelly, Rita ⁱ   Esteves, Jane ⁱ   Tedaldi, Ellen M ^j   Christian, Ramona A ^j   Walker Kornegay, Linda ^j   Marzouk, Joseph B ^k   Phelps, Roger T ^k   Rachel, Mark ^k,l   Sisneros, Silver ^l   Novak, Richard M ^m   Uy, Jonathan P ^m   Wendrow, Andrea ^m   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CERNER CORPORATION   (United States)

^c RTI INTERNATIONAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f ROSE MEDICAL CENTER   (United States)

^g INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^h Dupont Circle Physicians Group   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

^j TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Adult Immunology Clinic   (United States)

^l Fairmont Hospital   (United States)

^m UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

HAART; Renal disease; Serum phosphate; Tenofovir; Toxicity

Indexed keywords

CREATININE; PHOSPHATE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADENINE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; HYPOPHOSPHATEMIA; INCIDENCE; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 33747657216     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00407.x     Document Type: Article

References (26)

1. Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: A nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003; 23: 29-43.
2. Van Rompay KK, Brignolo LL, Meyer DJ et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48: 1469-1487.
3. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy) propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): Safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 323-333.
4. Izzedine H, Isnard-Bagnis C, Hulot JS et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18: 1074-1076.
5. Peyriere H, Reynes J, Rouanet I et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269-273.
6. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-1263.
7. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. J Am Med Assoc 2004; 292: 191-201.
8. Izzedine H, Hulot JS, Vittecoq D et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-746.
9. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003; 139: 313-320.
10. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
12. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Table for Grading the Severity of Adult and Pediatric Adverse Events. http://rcc.tech-res-intl.com/ tox_tables.htm 2004.
13. Cheng AK, Chen SS, Wulfsohn M, Toole JJ. 2 year long term safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized double-blind, placebo-controlled clinical trials. 9th European AIDS Conference Warsaw, Poland, October 2003 [Abstract 7.3/7].
14. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 93-95.
15. Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr 2005; 38: 301-304.
16. Badiou S, Merle DB, Terrier N et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2005; 5: 335-338.
17. Vigano A, Giacomet V, Merlo M et al. Long-term use of tenofovir in treatment-experienced children appears safe. 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland, November 2005 [Abstract 92].
18. Antoniou T, Raboud J, Chirhin S et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retrospective cohort study. HIV Med 2005; 6: 284-290.
19. Bringhurst FR, Demay MB, Krane SM, Kronenberg HM. Bone and mineral metabolism in health and disease, In: Kasper DL, Fauci AS, Longo DL, Brunwald E, Hauser SL, Jameson JL. eds. Harrison's Principles of Internal Medicine, 16th edn. New York, McGraw-Hill Co., Inc., 2004: 2241-2243.
20. Perazella MA, Brown E. Electrolyte and acid-base disorders associated with AIDS: An etiologic review. J Gen Intern Med 1994; 9: 232-236.
21. Lalezari JP, Stagg RJ, Kuppermann BD et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997; 126: 257-263.
22. Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. J Am Med Assoc 1999; 282: 2305-2312.
23. Perazella MA. Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325: 349-362.
24. Lochet P, Peyriere H, Le M et al. Assessment of renal abnormalities in 107 HIV patients treated with tenofovir. Therapie 2005; 60: 175-181.
25. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341-346.
26. Giacomet V, Mora S, Martelli L et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40: 448-450.